An observational study to evaluate the impact of the gene panel test FoundationOne CDx or FoundationOne Liquid CDx on treatment decision-making in metastatic and recurrent breast cancer throughout Japan as a whole.
Not Applicable
Recruiting
- Conditions
- Patients with stage IV or recurrent breast cancer who have distant metastases at registration
- Registration Number
- JPRN-UMIN000038065
- Lead Sponsor
- Japan Breast Cancer Research Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with active invasive double cancer within 5 years or patients with active invasive double cancer that currently needs treatment.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the accessibility to matched therapies and the access rate to clinical trials that were recommended by FoundationOne CDx or FoundationOne Liquid CDx genome profiling results The matched therapy is defined as the therapy determined by the expert panel according to the results of the F1CDx or F1LCDx Clinical trials include either single arm development studies or clinical trials
- Secondary Outcome Measures
Name Time Method